Dr. Reddy’s Laboratories Ltd.

Company Snapshot

Founded: 1984
Entity Type: Public
Employees: 26,944
Region: U.S.
Revenue: $3,932.5 Millions
Revenue Year: 2024
Headquarter: Hyderabad, Telangana, India
Key Geographics: U.S., India, Russia, Rest of the World
Corporate Address: 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500034, India Tel. +91-40-4900-2900 www.drreddys.com

Company Overview

Dr. Reddy’s is a pharmaceutical company with products ranging from generics, over-the-counters medicines, and APIs to biologics and proprietary products. The company’s Custom Pharma Services (CPS) business unit provides third parties with pharmaceutical development and manufacturing services and solutions for starting materials, intermediates, active ingredients, and finished dosage forms. The therapeutic areas where Dr. Reddy’s focuses include oncology, gastroenterology, cardiovascular, diabetes, and pain management. Dr. Reddy’s has 22 manufacturing sites and eight R&D facilities across the globe. Aurigene Oncology Ltd., a wholly owned subsidiary of Dr. Reddy’s, is working on chimeric antigen receptor (CAR) T-cell therapy for oncology in India.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Dr. Reddy’s Laboratories Ltd. In Reports

Substance Use Disorder Treatment: Global Markets to 2030

BCC Research detailed report on Substance Abuse, Addiction and Treatment Markets revenue ($ Million) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030.

Global Markets for Generic Drugs

BCC Research Market Analyst says global market for generic drugs is expected to grow from $435.3 billion in 2023 and projected to reach $655.8 billion by the end of 2028, at a CAGR of 8.5%.

Best Selling Pharmaceutical Drugs in 2021

BCC Research Market Analysis Report for Best Selling Pharmaceutical Drugs in 2021. Pharmaceutical Drugs market can grow from $1.3 tln to $1.8 tln in 2027.

Company's Business Segments

  • Global Generics : Branded and unbranded prescription medicine, Over The Counter (otc) Pharmaceutical products, Biosimilars business
  • Pharmaceutical Services and Active Ingredients (PSAI) : Active Pharmaceutical Ingredients (APIs), Aurigene Pharmaceutical Services (APSL)

Applications/End User Industries

  • Research and Development
  • Manufacturing and Supply Chain
  • Digitalisation
AI Sentiment